EyePoint, Inc. Common Stock (EYPT)

Price$11.78

Value ScoreD

Growth ScoreF

Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)-28.49%

Price vs S&P 500 (4W)-13.75%

VGM Score24.32

Market Capitalization$987.65M

All Metrics

Book Value / Share (Quarterly)$2.76

P/TBV (Annual)1.24x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-8.83%

Cash Flow / Share (Quarterly)$-3.25

Price vs S&P 500 (YTD)-43.68%

Gross Margin (TTM)76.51%

Net Profit Margin (TTM)-3566.63%

EPS (TTM)$-3.50

10-Day Avg Trading Volume1.09M

EPS Excl Extra (TTM)$-3.50

Revenue Growth (5Y)-1.85%

EPS (Annual)$-3.17

ROI (Annual)-75.78%

Gross Margin (Annual)93.41%

Net Profit Margin (5Y Avg)-320.16%

Cash / Share (Quarterly)$2.67

Revenue Growth QoQ (YoY)-97.15%

ROA (Last FY)-63.73%

Revenue Growth TTM (YoY)-86.41%

EBITD / Share (TTM)$-3.61

ROE (5Y Avg)-55.80%

Operating Margin (TTM)-3700.89%

Cash Flow / Share (Annual)$-2.94

P/B Ratio4.29x

P/B Ratio (Quarterly)4.67x

Net Income / Employee (Annual)$-1,083,900

EV / Revenue (TTM)119.49x

Net Interest Coverage (TTM)-95.46x

ROA (TTM)-90.15%

EV / EBITDA (TTM)139.35x

EPS Incl Extra (Annual)$-3.17

Current Ratio (Annual)8.88x

Quick Ratio (Quarterly)5.97x

3-Month Avg Trading Volume1.20M

52-Week Price Return42.79%

Revenue / Employee (TTM)$35,600

Tangible BV / Share (Quarterly)$2.83

P/S Ratio (Annual)31.48x

Asset Turnover (Annual)0.09x

52-Week High$19.11

Operating Margin (5Y Avg)-333.51%

EPS Excl Extra (Annual)$-3.17

CapEx CAGR (5Y)55.57%

Tangible BV CAGR (5Y)35.00%

26-Week Price Return-20.57%

Quick Ratio (Annual)8.28x

13-Week Price Return-25.25%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)6.66x

Enterprise Value$909.94M

Revenue / Share Growth (5Y)-30.71%

Asset Turnover (TTM)0.03x

Book Value / Share Growth (5Y)29.31%

Revenue / Employee (Annual)$146,600

Inventory Turnover (Annual)1.00x

Pretax Margin (Annual)-738.53%

Cash / Share (Annual)$3.70

3-Month Return Std Dev55.02%

Gross Margin (5Y Avg)86.50%

Net Income / Employee (TTM)$-1,269,200

ROE (Last FY)-75.78%

Net Interest Coverage (Annual)-27.76x

EPS Basic Excl Extra (Annual)$-3.17

P/FCF (TTM)17.44x

Receivables Turnover (TTM)9.52x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-3.50

Receivables Turnover (Annual)49.87x

ROI (TTM)-110.54%

P/S Ratio (TTM)129.70x

Pretax Margin (5Y Avg)-319.91%

Revenue / Share (Annual)$0.43

Tangible BV / Share (Annual)$2.83

Price vs S&P 500 (52W)18.42%

Year-to-Date Return-35.52%

5-Day Price Return-10.42%

EPS Normalized (Annual)$-3.17

ROA (5Y Avg)-38.76%

Net Profit Margin (Annual)-739.42%

Month-to-Date Return-13.25%

Cash Flow / Share (TTM)$-2.64

EBITD / Share (Annual)$-3.29

Operating Margin (Annual)-775.98%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-48.55%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-3.50

P/TBV (Quarterly)1.24x

P/B Ratio (Annual)4.94x

Inventory Turnover (TTM)1.06x

Pretax Margin (TTM)-3563.62%

Book Value / Share (Annual)$3.70

Price vs S&P 500 (13W)-33.51%

Beta1.73x

P/FCF (Annual)97.40x

Revenue / Share (TTM)$0.09

ROE (TTM)-110.54%

52-Week Low$7.94

vGradeD

gGradeF

mGradeC

vgmGradeD

Show chart for

Earnings Surprise History

Q1 26-0.99est. -0.82

Analyst Recommendations

Mar 2026

Apr 2026

May 2026

Jun 2026

4.28

Industry Peers — Lab Analytical Instruments(24)

Symbol	Value Score	Growth Score	Momentum Score	Price
EYPTEyePoint, Inc. Common Stock	D	F	C	$11.78
AAgilent Technologies Inc.	C	C	B	$135.44
WATWaters Corp	D	C	C	$365.36
ILMNIllumina Inc	D	D	B	$162.32
MTDMettler-Toledo International	D	C	C	$1154.33
RVTYRevvity, Inc.	C	D	C	$98.37
BRKRBruker Corporation	D	D	B	$56.39
BIOBio-Rad Laboratories, Inc.Class A	C	F	B	$294.32
BIO.BBio-Rad Laboratories, Inc. Class B	C	F	B	$304.15
AVTRAvantor, Inc.	B	D	C	$9.16
TXG10x Genomics, Inc. Class A Common Stock	D	C	A	$31.04

About

EyePoint Inc is a clinical-stage biopharmaceutical company developing sustained-release therapeutics for serious retinal diseases, with the goal of improving patient outcomes while reducing treatment burden and follow-up care frequency. Its pipeline includes DURAVYU, a sustained-release product candidate for retinal diseases, and EYP-2301, an early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting vascular stability in conditions like wet age-related macular degeneration.